FDA warns Nobles Medical Technology II over oversight failures in NobleStitch EL clinical study.
What happened
FDA inspected Nobles Medical Technology II as sponsor of the STITCH study from Oct. 16 to Oct. 20, 2023, and found serious violations of investigational device rules. The agency cited missing study information for investigators, inadequate monitoring and institutional review board (IRB) approvals, and missing signed agreements and financial disclosures. FDA also noted similar problems at the company's largest enrolling site in Italy and said the study was suspended.
What FDA found
Failed to give investigators necessary study information such as signed protocols, investigational brochures, and labeling.
21 CFR 812.40Failed to ensure proper monitoring, including no written monitoring plan and site reports that did not list documents reviewed, findings, or source-document comparisons with case report forms.
21 CFR 812.40Failed to document IRB approvals and continuing review for several sites and protocol versions.
21 CFR 812.40Failed to show that clinical investigators and the monitor were qualified by training and experience, including by not providing curricula vitae.
21 CFR 812.43(a) and (d)Signed investigator agreements did not include a statement that the investigator would supervise all testing of the device involving human subjects.
21 CFR 812.43(c)(4)(i)Did not obtain financial disclosure records from any site.
21 CFR 812.43(c)(5)
What FDA wants
FDA asks the company to provide documentation of corrective and preventive actions within 15 working days, including projected completion dates and a plan to monitor effectiveness. The response must reference CTS# G180296/E003 and be emailed to Albert.Rodriguez@fda.hhs.gov.
Who should pay attention
- sponsors of investigational device studies
- contract research organizations and monitors
- IRBs and sites enrolling in device trials
This is a summary. Read the original letter on fda.gov.